Brokerages Expect Allogene Therapeutics Inc (NASDAQ:ALLO) to Announce -$0.47 EPS
Brokerages predict that Allogene Therapeutics Inc (NASDAQ:ALLO) will post ($0.47) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Allogene Therapeutics’ earnings. The lowest EPS estimate is ($0.54) and the highest is ($0.37). The company is scheduled to issue its next quarterly earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that Allogene Therapeutics will report full-year earnings of ($1.94) per share for the current fiscal year, with EPS estimates ranging from ($2.10) to ($1.45). For the next fiscal year, analysts forecast that the company will post earnings of ($2.37) per share, with EPS estimates ranging from ($2.89) to ($1.71). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Allogene Therapeutics.
Allogene Therapeutics (NASDAQ:ALLO) last announced its earnings results on Tuesday, May 7th. The company reported ($0.32) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.08.
Shares of NASDAQ ALLO opened at $26.66 on Thursday. Allogene Therapeutics has a 1-year low of $21.67 and a 1-year high of $35.55. The stock has a market capitalization of $3.27 billion and a price-to-earnings ratio of -4.05. The company has a quick ratio of 17.48, a current ratio of 17.48 and a debt-to-equity ratio of 0.05.
In related news, insider Alison Moore sold 48,828 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $26.76, for a total transaction of $1,306,637.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Group Holdings (Sbs) Advis Tpg sold 1,918,755 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $29.38, for a total transaction of $56,373,021.90. The disclosure for this sale can be found here.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC acquired a new position in Allogene Therapeutics during the fourth quarter valued at approximately $27,000. Legal & General Group Plc acquired a new position in Allogene Therapeutics during the fourth quarter valued at approximately $89,000. Partner Investment Management L.P. acquired a new position in Allogene Therapeutics during the fourth quarter valued at approximately $135,000. NumerixS Investment Technologies Inc acquired a new position in Allogene Therapeutics during the first quarter valued at approximately $136,000. Finally, Citigroup Inc. acquired a new position in Allogene Therapeutics during the fourth quarter valued at approximately $152,000. 53.47% of the stock is owned by institutional investors and hedge funds.
About Allogene Therapeutics
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.
Read More: Why does a company issue an IPO?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.